Verona Financial Statements From 2010 to 2024

VRNA Stock  USD 37.86  0.99  2.55%   
Verona Pharma financial statements provide useful quarterly and yearly information to potential Verona Pharma PLC investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Verona Pharma financial statements helps investors assess Verona Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Verona Pharma's valuation are summarized below:
Gross Profit
112 K
Market Capitalization
3.2 B
Enterprise Value Revenue
527.2779
Revenue
5.6 M
Earnings Share
(2.00)
We have found one hundred twenty available fundamental trend indicators for Verona Pharma PLC, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Verona Pharma PLC current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 3 B, whereas Enterprise Value is forecasted to decline to about 1.3 B.

Verona Pharma Total Revenue

500,365

Check Verona Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verona Pharma's main balance sheet or income statement drivers, such as Interest Expense of 2.2 M, Selling General Administrative of 45.9 M or Other Operating Expenses of 71.2 M, as well as many indicators such as Price To Sales Ratio of 4.1 K, Dividend Yield of 0.0 or PTB Ratio of 6.01. Verona financial statements analysis is a perfect complement when working with Verona Pharma Valuation or Volatility modules.
  
Check out the analysis of Verona Pharma Correlation against competitors.

Verona Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets323.5 M308.1 M110.8 M
Slightly volatile
Total Current Liabilities7.7 M8.7 M9.2 M
Slightly volatile
Total Stockholder Equity261.7 M249.3 M92.8 M
Slightly volatile
Accounts Payable3.7 M3.5 M2.1 M
Slightly volatile
Cash285.4 M271.8 M86.5 M
Slightly volatile
Non Current Assets Total19.3 M18.4 M6.8 M
Slightly volatile
Cash And Short Term Investments285.4 M271.8 M95.3 M
Slightly volatile
Net Receivables11.5 M11 M5.8 M
Slightly volatile
Common Stock Shares Outstanding75.3 M79.3 M412.6 M
Slightly volatile
Liabilities And Stockholders Equity323.5 M308.1 M110.8 M
Slightly volatile
Other Current Assets7.3 MM3.1 M
Slightly volatile
Other Stockholder Equity629.5 M599.5 M214.4 M
Slightly volatile
Total Liabilities61.8 M58.8 M17.9 M
Slightly volatile
Total Current Assets304.2 M289.7 M104 M
Slightly volatile
Common Stock44.9 M42.8 M14.7 M
Slightly volatile
Other Current Liabilities5.9 MM6.8 M
Slightly volatile
Property Plant And Equipment NetM2.9 M703.3 K
Slightly volatile
Good Will466 K490.5 K1.3 M
Slightly volatile
Property Plant And Equipment GrossM2.9 M616.8 K
Slightly volatile
Intangible Assets4.4 M4.2 M2.2 M
Slightly volatile
Net Tangible Assets277.6 M264.4 M91 M
Slightly volatile
Property Plant Equipment1.1 M1.1 M453.3 K
Slightly volatile
Capital Surpluse97.2 M136.7 M77.7 M
Slightly volatile
Net Invested Capital174.8 M297.7 M136.2 M
Slightly volatile
Net Working Capital165.8 M281 M130.9 M
Slightly volatile
Capital Stock29.4 M42.8 M16.2 M
Slightly volatile

Verona Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative45.9 M43.7 M11.7 M
Slightly volatile
Other Operating Expenses71.2 M67.8 M35.7 M
Slightly volatile
Total Operating Expenses70.5 M67.2 M35.5 M
Slightly volatile
Depreciation And Amortization713.6 K679.6 K404.5 K
Slightly volatile
Research Development19.8 M17.3 M22.6 M
Slightly volatile
Interest Income11.9 M11.3 M1.9 M
Slightly volatile
Reconciled Depreciation543.6 K620 K344.4 K
Slightly volatile
Selling And Marketing Expenses16.7 M17.4 M21.4 M
Slightly volatile

Verona Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow285.4 M271.8 M86.5 M
Slightly volatile
Stock Based Compensation20 M19 M7.6 M
Slightly volatile
Begin Period Cash Flow239.2 M227.8 M65.6 M
Slightly volatile
Depreciation212 K116 K237.1 K
Slightly volatile
Other Cashflows From Investing Activities1.1 MM532.9 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.1 K4.3 K26.5 K
Very volatile
PTB Ratio6.016.3215328
Slightly volatile
Days Sales Outstanding8.1 K8.5 K560.8 K
Slightly volatile
Book Value Per Share3.33.14481.5424
Slightly volatile
Invested CapitalM5.7 M6.2 M
Slightly volatile
Average Payables1.2 M1.2 M1.1 M
Slightly volatile
Stock Based Compensation To Revenue33.6835.46187
Pretty Stable
Capex To Depreciation0.04980.05241.8849
Slightly volatile
PB Ratio6.016.3215328
Slightly volatile
EV To Sales3.6 K3.8 K25 K
Very volatile
Inventory Turnover0.150.160.1458
Very volatile
Days Of Inventory On Hand5.0E-45.0E-42.2 K
Slightly volatile
Payables Turnover0.180.19460.4528
Pretty Stable
Sales General And Administrative To Revenue17.1718.07452
Pretty Stable
Research And Ddevelopement To Revenue1181241.9 K
Pretty Stable
Capex To Revenue0.06920.072818.7298
Pretty Stable
Cash Per Share3.63.42851.5647
Slightly volatile
Days Payables Outstanding1.3 K1.9 K1.5 K
Slightly volatile
Intangibles To Total Assets0.00170.00180.1711
Slightly volatile
Net Debt To EBITDA3.994.201511.7551
Slightly volatile
Current Ratio18.5133.330416.0596
Pretty Stable
Tangible Book Value Per Share3.293.13791.5123
Slightly volatile
Receivables Turnover0.04220.04440.5227
Slightly volatile
Graham Number7.316.96654.4152
Slightly volatile
Shareholders Equity Per Share3.33.14481.5424
Slightly volatile
Debt To Equity0.20.19410.0528
Slightly volatile
Capex Per Share4.0E-44.0E-40.0026
Pretty Stable
Graham Net Net2.932.78991.327
Slightly volatile
Average Receivables3.4 M3.2 M3.3 M
Slightly volatile
Revenue Per Share0.00590.00620.1004
Slightly volatile
Interest Debt Per Share0.670.63630.1168
Slightly volatile
Debt To Assets0.160.1570.0449
Slightly volatile
Price Book Value Ratio6.016.3215328
Slightly volatile
Days Of Payables Outstanding1.3 K1.9 K1.5 K
Slightly volatile
Company Equity Multiplier0.911.2361.1559
Very volatile
Long Term Debt To Capitalization0.170.16250.0449
Slightly volatile
Total Debt To Capitalization0.170.16250.0479
Slightly volatile
Debt Equity Ratio0.20.19410.0528
Slightly volatile
Quick Ratio18.7433.330416.0683
Pretty Stable
Net Income Per E B T0.730.98470.894
Very volatile
Cash Ratio15.6631.266914.2168
Pretty Stable
Days Of Inventory Outstanding5.0E-45.0E-42.2 K
Slightly volatile
Days Of Sales Outstanding8.1 K8.5 K560.8 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.151.0371
Pretty Stable
Price To Book Ratio6.016.3215328
Slightly volatile
Fixed Asset Turnover0.540.5750.9723
Slightly volatile
Debt Ratio0.160.1570.0449
Slightly volatile
Price Sales Ratio4.1 K4.3 K26.5 K
Very volatile
Asset Turnover0.00150.00160.037
Pretty Stable
Price Fair Value6.016.3215328
Slightly volatile
Operating CycleKK4.6 K
Slightly volatile
Cash Conversion Cycle3.2 K6.3 K2.8 K
Slightly volatile

Verona Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapB1.6 B4.2 B
Pretty Stable
Enterprise Value1.3 B1.4 BB
Pretty Stable

Verona Fundamental Market Drivers

Cash And Short Term Investments271.8 M

Verona Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Verona Pharma Financial Statements

Verona Pharma stakeholders use historical fundamental indicators, such as Verona Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Verona Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Verona Pharma's assets and liabilities are reflected in the revenues and expenses on Verona Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Verona Pharma PLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue 1.15  1.09 
Total Revenue526.7 K500.4 K
Cost Of Revenue679.6 K713.6 K
Stock Based Compensation To Revenue 35.46  33.68 
Sales General And Administrative To Revenue 18.07  17.17 
Research And Ddevelopement To Revenue 123.75  117.56 
Capex To Revenue 0.07  0.07 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(129.92)(136.42)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Verona Pharma PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verona Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verona Pharma Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verona Pharma Plc Stock:
Check out the analysis of Verona Pharma Correlation against competitors.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.00)
Revenue Per Share
0.07
Return On Assets
(0.28)
Return On Equity
(0.78)
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.